4D Molecular Therapeutics, Inc. (FDMT)

From the record

4D Molecular Therapeutics, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

4D Molecular Therapeutics, Inc.'s 7 filed years say what it did: revenue went from $7 million in fiscal 2019 to $85 million in fiscal 2025, up 51.7% a year; it rose in 4 of 6 years; the deepest fall was 100% from fiscal 2023 to fiscal 2024; net income was positive in 0 of 7 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, 4D Molecular Therapeutics, Inc. lost about 28 cents for every dollar of shareholders' money. Leverage: it owed about 11 cents per dollar of assets, and net share issuance: its share count grew 7.4% over the year (the filed statements).

From the record

4D Molecular Therapeutics, Inc.'s standing among 102 graded names in its industry family: revenue of $85 million in fiscal 2025 ranks in the top 31% by size; a net margin of -164.4% ranks in the top 43%; revenue growth of 200.8% a year over the last 3 filed years ranks in the top 7% (its annual reports).

From the record

4D Molecular Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: no one files under a chief executive's title, so that part is not read; the 12 officers and directors filing in the last fifteen months have been on the record a median of 5.9 years (top 33%); 6 officer or director changes were reported on Form 8-K since 2023-11-13, against the 12 people in charge now (bottom 47%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

4D Molecular Therapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $60 million against no long-term debt tagged leaves 10.6% of its assets as net cash, bottom 16% of its family; cash from operations less capital spending is -128.6% of revenue (top 43%); research spending of 229.7% of revenue (top 42%) (its annual report).

From the record

4D Molecular Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 200.8% a year over the last three filed years against 51.7% over all 7, speeding up (top 3% of its family); the newest year grew 231419% (top 1%); research spending grew 34.6% a year (top 6%); capital spending grew -64% a year (bottom 17%) (its annual reports). 4D Molecular Therapeutics, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

4D Molecular Therapeutics, Inc.'s newest year against its own record: revenue of $85 million in fiscal 2025 came in 2114491.9% above the $4 thousand its prior three years' pace pointed to (top 1% of its family); net income of $140 million against a prior three-year average of $123 million (bottom 34%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 1%) (its annual reports).